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Vincent Barlogis,1 Laurence Glasman,2 Corine Brunet,2
Anderson Dieudonne Loundou,3 Claude Lemarie,4 Claire Galambrun,1 Isabelle Thuret,1
Catherine Curtillet,1 Marion Le Meignen,1 Fanette Bernard,1 Herve Chambost,1
Boris Calmels,4 Christophe Picard,5 Christian Chabannon,4 Franc¸oise Dignat-George,2
Gerard Michel1Westudied lymphocyte recovery in 88 childrenwho consecutively underwent unrelated cord blood transplan-
tation formalignant (n5 64) or nonmalignant (n5 24) diseases. All children but 3 receivedmyeloablative con-
ditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and
median follow-up was 40 months (10-136 months). The median dose of infused viable CD451 cells
(vCD45)was 3.35 107/kgwith a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic end-
points were: time to achieve CD31 .500 and 1500/mm3, CD41 .500/mm3, CD81 .250/mm3, CD191
.200/mm3, natural killer .100/mm3. These endpoints were analyzed through the use of cumulative curves
for estimating incidence over time in the context of competing risks, and through Fine and Gray models to
assess prognostic factors. The median time to reach these endpoints was 33, 97, 214, and 340 days for natural
killer, B, CD8, and CD4 cells, respectively. In multivariate analysis, a high infused vCD45 cell dose improved
CD3 (P 5 .014) and CD4 (P 5 .032) reconstitutions. A young recipient age also favored CD3 recovery (P 5
.013). With patients grouped according to vCD45 cell dose quartiles, the threshold for a better recovery
was 3.35 107/kg. Considering the ratio vCD45/TNC, this “immune recovery based” threshold corresponds
to a higher cell dose than the minimum usually recommended dose for myelogenous engraftment. This may
have important implication for UCB selection.
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Since initial studies reported by Kurtzberg et al. [1],
Wagner et al. [2], and Gluckman et al. [3], hematopoi-
etic stemcell transplantation (HSCT) fromanunrelated
cord blood unit (UCBT) has become an accepted
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The increasing use of CB, relative to bone marrow
transplantation (BMT), in the unrelated donor setting
is explained by such reasons as noninvasive hematopoi-
etic collection, prompt availability of UCB units, less
stringent criteria for HLA matching, lower incidence
and severity of graft-versus-host disease (GVHD), and
overall similar outcomes with both types of grafts in
children [5-7] and adults [8,9]. Despite the low
incidence of GVHD, relapse rate of leukemia appears
to be similar after UCBT or unrelated BMT [10,11].
Nevertheless, UCBT remains associated with a high
incidence of life-threatening infections, especially
during the early posttransplant period [10,12,13].
Infection-related mortality is the major cause of
nonrelapse mortality following UCBT, and is often di-
rectly related to delayed immune recovery [7,14,15].
Several reports have described lymphocyte subset
reconstitution and factors affecting their speed of
recovery after UCBT [16-20]. Although these studies
constitute major contributions, their conclusions may109
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such as relatively low number of transplanted patients,
patient selection leading to potential bias, and
multicentric data resulting in heterogeneity of
transplant procedures and evaluation of posttransplant
immune recovery. Here, we report a detailed analysis
of lymphocyte subset recovery homogeneously
conducted in 88 children who consecutively received
UCBT in a single pediatric transplant center.MATERIALS AND METHODS
Patients
Patients treated in our pediatric transplant pro-
gram were eligible for the study if they met all the
following criteria: (1) having received HSCT with a
single unrelated cord blood unit, (2) being 18 years
old or less at time of transplant, (3) being in remission
at the time of transplant for children with malignant
diseases. Eighty-eight children consecutively trans-
planted between February 1997 and December 2007
fulfilled these criteria and were included in the study.
Evaluation of HLA Compatibility
and Prefreezing Transplant Dose
Donor-recipientHLAmatchingwas assessed at ge-
neric level for HLA-A and -B (ie, low/intermediate res-
olutionmolecular typing).High-resolution genotyping
ofHLADRB1of recipients andUCBwasperformedby
polymerase chain reaction-sequence specific primer
(PCR-SSP). HLA compatibility was expressed as the
number of identical loci among 6.
CB units were obtained from CB banks located in
France (n 5 45), the United states (n 5 18), Germany
(n5 7), theUnitedKingdom (n5 5), Italy (n5 5), Spain
(n5 4), Belgium (n5 1), and Denmark (n5 1), which
provided the prefreezing total nucleated cell (TNC)
dose for each unit.
Evaluation of Transplant Cell Dose and Quality
Controls on Thawed CB
The infused transplanted cell doses were evaluated
by the TNC count as well as by absolute CD341 and
CD451 cells counts. Absolute counts of CD341 and
CD451 cells were determined using the Stem-Kit nu-
meration kit (Beckman-Coulter Company, Fullerton,
CA), as previously described [21]. Briefly this commer-
cially available diagnostic kit includes the viability dye
7-amino actinomycin D (7-AAD). Thus, the viable
CD45 (vCD45) count corresponds to viable infused
cells expressing the CD45 common leukocyte antigen.
Including fluorescent microspheres, this single plat-
form assay allows for a quantification of viable
CD341 and CD451 cells (vCD341 and vCD451, re-
spectively) [22,23]. Data acquisitions and analyseswere performed on a FACSCalibur 4-color flow
cytometer using the Cellquest software (Becton
Dickinson Immunocytometry System [BDIS], San
Jose, CA). The gating strategy is adapted from
ISHAGE guidelines following recommendation for
cord blood CD34 cell enumeration [22].
Evaluation of Lymphocyte Subsets Recovery
and Blood Chimerism
All recipients underwentblood samples at days130,
160, 190, months 16, 19, 112, 118, 124, and then
every year. Phenotypic analysis of blood lymphocytes
was performed using 4-color immunofluorescence
flow cytometry to characterize the following lympho-
cyte subsets: CD31 T lymphocytes, CD31CD41 and
CD31CD81 T lymphocytes, CD191 B lymphocytes,
and CD32/CD161561 natural killer (NK) lympho-
cytes.
Chimerismwas analyzed inperipheral blood cells of
all recipients at days 130, and 190, and months 16,
19, 112, 118, and124 after transplantation. Chime-
rism was determined by real-time PCR amplification
of single nucleotide polymorphisms. Total chimerism
was defined as .99% donor-derived cells, mixed chi-
merism as the presence of 20% to 99% donor-derived
cells, and autologous recovery as hematopoietic recov-
ery (absolute neutrophil count [ANC] .0.5 G/L and
platelets.20 G/L) with.80% blood host chimerism.
Endpoints
Standard definitions were used for common post-
transplant endpoints, namely, overall survival (OS), re-
lapse incidence, treatment-related mortality (TRM),
acuteGVHD(aGVHD), and chronicGVHD(cGVHD).
Several immunologic endpoints were chosen for their
potential clinical significance: time to achieve a CD31
cell count .500/mm3, CD3 .1500/mm3, CD4
.500/mm3, CD8 .250/mm3, CD19 .200/mm3,
and CD32CD561 .100/mm3.
Statistical Methods
November 1, 2008, was used as the reference date,
that is, the day when we locked data on patient out-
comes. As for OS, Kaplan-Meier estimates provided
estimated incidence over time. However, the other
endpoints shared a competing risk setting, meaning
patients could develop events that avoid the occur-
rence of the event of interest. As an example, after
death or relapse before achievement of an immuno-
logic endpoint, no further immunologic recovery
could occur. Therefore, these endpoints (TRM, re-
lapse, and all endpoints used for assessment of immu-
nologic recovery) were analyzed through the use of
cumulative incidence curves for estimating incidence
over time [24] and through Fine and Gray models
[25] to assess prognostic factors. In this study, TRM,
Table 1. Patients and Cord Blood Units Characteristics
Variables N %
Recipients
Median age, years (range) 5.6 (0.1-18)
Median weight, kg (range) 20 (3.5-63)
Male/Female 45/43 51.1/48.9
Positive CMV serology 34 38.6
Disease
Malignancies
ALL 43 48.8
AML 10 11.3
Myelodysplastic syndrome 4 4.5
Non-Hodgkin lymphoma 7 8.0
Nonmalignant disorders
Bone marrow failure syndrome 7 8
Immunodeficiencies 6 6.8
Metabolic disorders 11 12.5
Donor
HLA matched 9 10.2
1 HLA disparity 36 41
2 HLA disparities 40 45.5
3 HLA disparities 3 3.4
ABO matched 40 45.5
Transplant
Median (IQR) NC collected  107/kg 7.10 (4.97-10.69)
Median (IQR) NC infused  107/kg 5.35 (3.88-8.10)
Median (IQR) vCD45 infused  107/kg 3.35 (2.33-4.62)
Ratio vCD45 infused/NC collected 0.46 (0.36-0.55)
Median (IQR) CD34 infused  106/kg 0.16 (0.10-0.27)
Median (IQR) CD3 infused  106/kg 8.75 (5.94-12.54)
Median (IQR) CD3-56+ infused  106/kg 2.92 (1.86-4.66)
Median (IQR) CFU-GM infused  104/kg 1.34 (0.44-2.6)
Conditioning regimen*
TBI containing 49 55.7
Busulfan containing 36 41
CMV indicates cytomegalovirus; ALL, acute lymphoblastic leukemia;
AML, acute myelogenous leukemia; NC, total nucleated cells; TBI,
total body irradiation; IQR, interquartile range.
*All patients received antithymocyte globulin 2.5 mg/kg/day over 3 days.
Three patients underwent a nonmyeloablative conditioning regimen be-
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recovery were considered as competing risk for immu-
nologic recovery.
Variables studied for their potential impact on lym-
phocyte recovery included recipient age, weight, sex,
pretransplant cytomegalovirus (CMV) serology, dis-
ease (malignancy or not), graft-recipient HLA match
(6 or 5 of 6 versus less), graft cell dose, conditioning
regimen (with or without total body irradiation
[TBI]), and aGVHD. These variables were tested in
the univariate analysis as well as in the multivariat
models. Cause-specific hazard ratios (HR) were esti-
mated with 95% confidence intervals (95% CI).
Among variables studied for their potential impact
on lymphocyte recovery, graft cell dose was described
by 5 related variables: collected and infused TNC, in-
fused viable CD341 and CD451 cell dose, and infused
CD31 cell dose. Therefore, the influence of transplant
cell dose was investigated by performing 5 different
multivariate analyses, each of these analyses using 1
of the variables described. Additionally, Spearman
rank correlation coefficient was used to estimate corre-
lation between these 5 related variables. Unlike all
other studied variables, aGVHD cannot be defined at
the time of transplantation and can occur until day
100. Consequently, the impact of aGVHD on immu-
nologic recovery required a specific statistical analysis
beginning at day100 posttransplant.
All statistical analyses were performed using the
SPSS version 15.0.1 (SPSS Inc., Chicago, IL) and the
R 2.7.2 software package; the cumulative incidence
function has been estimated using the cmprsk package.cause of their diseases, which were extremely susceptible to the effects
of chemoradiotherapy: Fanconi’s anemia, congenital dyskeratosis, and
XIAP defect.RESULTS
Patients and Cord Blood Characteristics
Table 1 shows characteristics of the 88 patients.
Their median age at the time of transplantation was
5.6 years (range: 0.1-18 years) and the median follow-
up period was 40 months (range: 10-136 months).
Sixty-four of them had malignancy and 24 nonmalig-
nant disease. Most received a 4 of 6 (n 5 40) or a 5 of
6 (n 5 36) HLA identical CB unit. The median dose
of infused TNC, viable CD451 a cells, and viable
CD341 cells per kilogram recipient body weight
were, respectively, 5.35  107, 3.35  107, and 1.6 
105. The median ratio of viable CD45 cells infused/
TNC collected was 0.46.
Transplantation Procedure
All children but 3 received a myeloablative condi-
tioning regimen with either TBI (12 grays in 3 days
and 6 fractions) and cyclophosphamide (60 mg/kg/
day for 2 days) (n 5 49), or busulfan and cyclophos-
phamide (50 mg/kg/day for 4 days) (n 5 36). In all
cases, antithymocyte globulin (ATG) (rabbit ATG,Thymoglobine) was infused at a dose of 2.5 mg/kg/
day fromdays23 to21.GVHDprophylaxis uniformly
consisted of cyclosporine A (CsA) andmethylpredniso-
lone (fromday25 today5: 1mg/kg/day; 1.5mg/kg/day
throughdays 18; 1mg/kg/day through day 25; 0.75mg/
kg/day through days 32; 0.5 mg/kg/day through days
39; 0.25mg/kg/day throughdays 45 and stop).Children
with malignant diseases and nonmalignant disorders
received CsA for a total duration of 3 and 6 months,
respectively. aGVHD was treated with steroids. Gran-
ulocyte colony-stimulating factor was administered af-
ter transplantation to all patients.Global Outcomes
Themedian follow-upperiodwas 40months (range:
10-136). Probability of 1-year and 5-year OS were
69% 6 5.2% and 62% 6 4.1%, respectively. TRM
was 19.7%6 4.3%. Causes of death were relapse (n5
13), infections (n 5 11), GVHD (n 5 2), multisystem
organ failure (n 5 2), veno-occlusive disease (n 5 1),
and heart failure (n 5 1). The median time to reach
Figure 1. Cumulative incidence of lymphocyte subset recovery: time to achieve innate immunity cells reconstitution (A), B cell reconstitution (B),
CD3-cell reconstitution (C), and CD4- and CD8-cell reconstitution (D).
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quartile range [IQR]: 20-40) and 55 days (IQR: 42-90),
respectively. At 100 days after CBT, aGVHD had oc-
curred in 18.1% of the patients (grade II: n5 11, grade
III: n5 4, grade IV: n 5 1). cGVHD occurred in 9%
and was limited in all cases.
Lymphocyte Subsets Recovery
These outcomes are shown using cumulative inci-
dence curves (Figure 1).
Most of the patients reached the NK and B cell
endpoints: 69 and 62 patients, respectively. NK cells
recovered first with a median time to reconstitution
of 33 days and an IQR from 31 to 60 days, whereas
median time to B cells reconstitution was 97 days
(IQR: 68.5-144.8) (Figure 1A and B).
T cell recovery was slower (Figure 1C). Fifty-six
children achieved the early endpoint (CD3 .500/
mm3) and 42 patients the latest one (CD3 .1500/
mm3). Cumulative incidence estimates showed that
the median time to reach these endpoints were 214
days (IQR: 131-266) and 340 days (IQR: 254.8-404.8),
respectively. The reconstitution of CD81 T cells ap-
peared to be faster than CD4’s recovery (Figure 1D).
Factors Affecting Lymphocytes Recovery
The results of univariate and multivariate analyses
are shown in Table 2.In the multivariate analysis, infused vCD45 cell
dose (as a continuous variable) clearly improved the
early endpoint for T cell recovery (CD3 .500) with
an HR multiplied by 1.14 fold per 1  107 vCD45/kg
increment (P 5 .014), the CD4 (HR: 1.12, P 5 .032),
and the NK cell reconstitution (HR: 1.17, P 5 .033).
With patients grouped according to viable CD45 cell
dose quartiles, more rapid recovery occurred in recipi-
ent of more than 3.35  107/kg CD45 cell after
thawing of CB unit (Figure 2). This statistical correla-
tion was observed for early CD3 reconstitution (HR:
2.18, P 5 .003) and for CD4 reconstitution (HR:
2.33, P 5 .0036) (Figure 2B and D).
As shown in Figure 3, vCD45 cell dose was statis-
tically correlated with all 4 other variables used in this
study to describe graft cell dose, that is, collected
TNC, infused TNC, CD341, and CD31 cell doses
(P\.01 for each correlation). However, the influence
of graft cell dose on T cell recovery was no longer sta-
tistically significant when collected TNC, infused
TNC CD341, or CD31 cell doses were used in the
model instead of the infused vCD45 cell dose.
When the late endoint for T cell recovery was
analyzed (CD3\1500), we observed a better reconsti-
tution when age recipient was younger (HR: 0.91 for
each additional year of age, P 5 .013). None of the
variables showed a significant influence onCD8 cell re-
constitution. A negative pretransplant CMV serology
was associated with an improved B cell recovery of
Table 2. Univariate and Multivariate Analysis of Factors Affecting Lymphocyte Recovery
Univariate Multivariate*
Endpoints Significant Variable P Value Significant Variable HR 95% CI P Value
CD3 >500 vCD45 inf/kg .03 vCD45 inf/kg 1.14† 1.02-1.27 .014
< 3.35  107/kg 1.0 reference d
>3.35  107/kg 2.18 1.29-3.69 .003
CD3 >1500 Age .014 Age 0.91‡ 0.86-0.88 .013
CD4 >500 vCD45 inf/kg .009 vCD45 inf/kg 1.12 1.01-1.25 .032
< 3.35  107/kg 1.0 reference d
>3.35  107/kg 2.33 1.32-4.09 .0036
CD8 >250 None None
CD19>200 CMV negative serology .01 CMV negative serology 1.95 1.11-3.40 .019
NK >100 vCD45 inf/kg .041 vCD45 inf/kg 1.17† 1.01-1.18 .033
< 3.35  107/kg 1.0 reference d
>3.35  107/kg 1.71 1.08-2.70 .023
Malignant disease .06 Malignant disease 1.97 0.26-0.95 .034
CI indicates confidence interval; HR, hazard ratio; CMV, cytomegalovirus.
*The multivariate model presented here used infused vCD45 cell dose for graft cell dose evaluation.
†HR per each 1  107 vCD45/kg increase.
‡HR multiplied by 0.91 per each additional year.
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more rapid in children with malignant diseases than in
children without malignancies (HR: 1.97, P 5 .034).
Finally, occurrence of aGVHD had no apparent influ-
ence on immune cell recovery.DISCUSSION
Several studies have previously described lympho-
cyte subset recovery after unrelated CBT [16-20].
Nevertheless, our study may improve the
understanding of this process through 3 methodologic
characteristics. (1) We stuck to a homogeneous cohort
of 88 children who consecutively underwent UCBTs,
without any further selection based on survival
duration or relapse occurrence. The other series
reported lymphocyte recovery of smaller cohorts with
more selected patients, the larger study being the
Eurocord cohort, which included 49 UCBT recipients
[20]. (2) These 88 UCBTs were carried out in a single
pediatric transplant unit, which established relatively
good homogeneity for transplant procedures, notably
CB unit selection and manipulation, biologic controls
performed on the thawed and infused UCB, condition-
ing regimen, GVHD prevention, supportive care, and
immune monitoring in transplanted patients. (3) Lym-
phocyte recovery is subject to competing risks. There-
fore, we analyzed our data using cumulative incidence
curves for estimating incidenceover time in thepresence
of competing risks [24-26] as recommended by
European Group for Blood and Marrow Transplanta-
tion [27]. Thismethod gives a more accurate estimation
of endpoint sharing competing risks than the Kaplan-
Meir method, which is known for overestimating real
probabilities in this context, particularly when the event
of interest occurs late after transplant. Indeed, this kind
of statistical approach of competing risk is currently thestandard method for evaluating TRM and relapse after
HSCT and is increasingly used to describe granulocyte
and platelet reconstitution [27].Using such amethodol-
ogy implies the choice of thresholds to describe immu-
nologic endpoints. The use of normal values is not
a suitable solution because normal values in children
are highly dependent on the age, and because this age-
related variability has probably not the same clinical rel-
evance after UCBT. In fact, in this situation, stem cells
definitely rise from newborn blood, regardless of
recipient age. Moreover, immunologic efficiency does
not necessarily mean complete immunologic reconsti-
tution. In this study, we decided to chose 2 endpoints
for CD31 T cell reconstitution: (1) CD3 .500/mm3
as a relatively early event; (2)CD3.1500/mm3 as a later
endpoint. Other thresholds for lymphocyte recovery
were chosen close to the lower limit of adult normal
values [28,29].
In our study, lymphocyte recovery followed the
same sequence as in previous studies: NK cells first,
then B cells, whereas T cells reconstituted later [16-
20]. CBT as in other stem cell transplantation, the
innate immune system appears to recover much
earlier than adaptative immunity. In our series of
patients, median time to recovery for both neutrophil
and NK cells was 30 days, similarly to previously
reported data [3,12].
B cells recovered within a median of 3 months
posttransplant, whereas Thomson et al. [16] and Nie-
hues et al. [20] reported a normalization of the B cell
count after as late as 6 months. This might just reflect
differences in the definition of endpoints. Indeed, the
Eurocord study measured the time required to reach
the age-related normal value, whereas we chose to
study earlier endpoints for B cells as well as for T cells
recovery. Among all factors evaluated in our study for
their influence on B cell recovery, only the recipient
pretransplant CMV serology proved significant, with
Figure 2. Cumulative incidence of CD3.500 (A and B) and CD4.500 (C and D) cell recovery according to viable CD45-cell dose infused. A1 and C1
shows cumulative incidence of lymphocyte recovery according to quartileCD45-cell infused (q1:\2.27 107/kg, q2: 2.3-3.34 107/kg, q3: 3.35-4.61 107/
kg, q4:.4.79  107/kg).
114 Biol Blood Marrow Transplant 17:109-116, 2011V. Barlogis et al.an adverse effect in CMV positive recipients. To our
knowledge, this association had been reported only
once in a study by Kalwak et al. [30]. They observed
that CMV reactivation impaired B cell recovery in
allogeneic BMT recipients with GVHD. Whether
CMV status directly influences restoration of B lym-
phopoiesis, however, remains unclear because early
preemptive antiviral therapy might also adversely
affect immune reconstitution.
As in all previously published papers, T lympho-
cyte subsets were the last ones to recover. In our study,
this delay could be worsened by the use of ATG in theFigure 3. Correlation between infused viable CD45 cell dose (107/kg recip
CD34 cell dose or CD3 cell dose (106/kg recipient body weight). Rho (r): Simmune suppression regimen. Several studies have
demonstrated that ATG given pretransplant are still
active in the early posttransplant period and could
therefore interact with immune recovery [31]. Recon-
stitution of T cells after allogeneic HSCT proceeds
through 2 pathways. The early thymic-independent
pathway includes the antigen-driven expansion of
peripheral donor T cells, leading to limited TCR
diversity [32]. The late thymic-dependent pathway in-
volves selection of graft-derived lymphocyte precursor
cells generating a full T cell repertoire [33,34]. Our
study shows the influence of age on the latest T cellient body weight) and TNC cell dose (107/kg recipient body weight),
pearman correlation coefficient.
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to reflect particularly the thymic-dependent pathway.
Young recipients had a better T cell recovery than
older, probably reflecting the age-related decline of
thymic function [33].
We also showed that the number of viable CD45
cells was the most important factor for the early T cell
endpoint (CD3 .500) and for CD4 recovery. Among
graft cell doses, neither collected TNCs, nor infused
TNC, nor infused CD34 cells were found to sig-
nificantly alter lymphocyte recovery, whereas these
criteria are well-identified determinants of hematopoi-
etic reconstitution after UCBT [3,5,21,35,36]. Several
hypotheses can be made to explain this apparent
discrepancy. It is possible that the vCD45 cell dose,
which reflects the viable infused cells expressing the
common CD45 leukocyte antigen, may be a more
potent criteria to predict engraftment than the TNC
count, which includes nonviable cells and mature
erythroblasts. The high collected and infused TNC
dose in our study, which are 7.1 and 5.35  107/kg,
respectively, could also have contributed to the
lessening of the impact of this criterion by decreasing
the number of transplants with very low cell dose
and a very high risk of graft failure. Finally, one
could argue that criteria and thresholds defined to
predict hematopoietic engraftment are not necessarily
adequate when the endpoint is immunologic recovery.
Our study suggests that a minimum vCD45 cell
dose of 3.35  107/kg at infusion must be targeted to
achieve a faster lymphocyte reconstitution. Thus,
vCD45 count might be used as a predictive factor for
quality of T cell recovery and consecutively for the
risk of life-threatening infections [37,38]. However,
our findings are only based on the quantitative
recovery of lymphocyte subsets and not on qualitative
data such as specific functional T cell responses to
opportunistic agents and evaluation of thymic output.
This is an evident limitation of the study, which
reduces its potential implications on our knowledge of
posttransplant infection risk factors and infection-
related mortality. Further studies are required to better
describe relationships between post-UCBT lympho-
cyte subset recovery, immune function, infectious
complications, and survival.
Criteria for CB unit selection are currently based
on hematopoietic engraftment targets. All studies
strongly advised the use of a high cell dose, the mini-
mal cell dose recommended for transplantation usually
ranging from 2.5 to 4  107 collected TNC/kg
[3,12,39], or at least 1.7  105 CD34 cells/kg [21,36].
If our observations were confirmed, it would imply
choosing larger CB units. Indeed, in our study, the
amount of viable CD45 represented 46% of
cryopreserved TNCs. Aiming at this threshold of
3.35  107/kg at infusion therefore would imply
selecting grafts containing at least 7.2  107 TNC/kgat collection. From a clinical point of view, this goal is
very difficult to achieve with a single unit because CB
cell doses are intrinsically limited by the amount of
cells in the placenta. Moreover, narrowing selection
criteria to get a larger transplant might force
selection of less well-matched units, with the risks asso-
ciated with higher mismatching. To achieve such
a CD45 threshold, several possibilities must be investi-
gated, such as double cord blood transplantation or ex
vivo expansion of UCB. Concerning ex vivo expansion
of UCB, preclinical data are yet too preliminary to as-
sess its efficacy in terms of hematopoietic and immune
recovery [40,41]. Recent reports on double-unit
UCBTs have suggested better engraftment, more
GVHD, less relapse, and better survival than after
single-unit UCBTs [42-46]. Whether or not double-
unit transplantations may improve immunologic
recovery is an essential question that requires further
investigations.ACKNOWLEDGMENTS
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